Author | Ronald van Vollenhoven, PhD

Advice to rheumatologists in terms of staying up to date on newer treatment options entering the market for lupus.

Novel therapies in the pipeline that demonstrate potential advantages when used as treatment for systemic lupus erythematosus and lupus nephritis.

Recommendations for monitoring patients on novel therapies used to manage lupus nephritis and making decisions to taper or stop treatment.

The rationale for treating lupus nephritis with novel therapies such as belimumab and voclosporin.

The rationale for using a newer monoclonal antibody therapy, anifrolumab, to manage patients with systemic lupus erythematosus.

Indications for belimumab, a monoclonal antibody, as therapy for patients with systemic lupus erythematosus.